Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction

Author(s):
Voors, A.A.; Shah, S.J.; Bax, J.J.; Butler, J.; Gheorghiade, M.; Hernandez, A.F.; Kitzman, D.W.; McMurray, J.J.V.; Wirtz, A.B.; Lanius, V.; Laan, M. van der; Solomon, S.D.
Published
2018
Publication type
Article / Letter to editor
Partial adenosine A1-receptor agonistHeart failure with preserved ejection fractionHeart failure with reduced ejection fractionNeladenosonMitochondrial energetics
Date issued
2018-11-30
Language
English
Is part of
European Journal of Heart Failure (2018), Vol. 20, no. 11, p. 1601-1610
hdl
1887/94582
doi
10.1002/ejhf.1295